VEGFR-3 inhibitor materials and methods
View Patent ↗The present invention relates to the diagnosis, evaluation, and therapeutic intervention of disorders mediated by the activity of cell surface receptor VEGFR-3, which activity often is stimulated by VEGFR-3 ligands VEGF-C and VEGF-D. More particularly, the present invention identifies novel methods and compositions for the inhibition of VEGF-C/D binding to VEGFR-3. The compositions of the present invention will be useful in the inhibition of angiogenesis and lymphangiogenesis.
1. An isolated peptide comprising the amino acid sequence set forth in any one of SEQ ID NOs: 35-66, wherein the peptide is 8 to 25 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).
2. The isolated peptide according to claim 1 , wherein the peptide comprises amino- and carboxy-terminal cysteine residues.
3. The isolated peptide according to claim 1 , comprising the amino acid sequence set forth in any one of SEQ ID NOs: 35-43 and 55-66.
4. The isolated peptide of claim 1 , wherein said peptide comprises the sequence CGYWLTIWGC (SEQ ID NO: 35).
5. The peptide of claim 3 or claim 4 wherein the peptide is 10-25 amino acids in length.
6. An isolated peptide comprising the amino acid sequence set forth in SEQ ID NO: 34, wherein the peptide is 10 to 25 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).
7. The isolated peptide according to claim 6 , wherein the peptide comprises amino- and carboxy-terminal cysteine residues.
8. An isolated peptide comprising the amino acid sequence spanning amino acid residue 2 through amino acid residue 9 of any one of SEQ ID NOs: 35 and 55-58, wherein the peptide is 8 to 25 amino acids in length and binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).
9. The isolated peptide according to claim 8 , wherein the peptide comprises amino- and carboxy-terminal cysteine residues.
10. The isolated peptide of claim 8 wherein the peptide is 10 to 20 amino acids in length.
11. The isolated peptide according to claim 1 , 6 , or 8 , wherein said peptide further comprises an intramolecular bond between amino acid residues to form a cyclic peptide.
12. The isolated peptide according to claim 11 , wherein the peptide comprises amino- and carboxy-terminal cysteines, and the intramolecular bond comprises a disulfide bond between the cysteines.
13. The isolated peptide according to claim 1 , 6 , or 8 , wherein said peptide inhibits Vascular Endothelial Growth Factor C (VEGF-C) binding to the human VEGFR-3.
14. A peptide according to claim 1 , 6 or 8 , wherein the peptide is conjugated to a cytoxic agent or a label.
15. The peptide of claim 14 , wherein the label is selected from the group consisting of a radionuclide, a dye, an enzyme, and an enzyme substrate.
16. The peptide according to claim 14 , wherein the cytotoxic agent is a radioisotope.
17. The peptide according to claim 14 , wherein the cytotoxic agent is an anti-neoplastic pro-drug.
18. A chimeric protein comprising a peptide according to claim 1 , 6 or 8 attached to a tumor necrosis factor.
19. A chimeric protein comprising a peptide according to claim 1 , 6 or 8 attached to an antibody or binding fragment thereof.
20. The isolated peptide of claim 1 , 6 , or 8 , wherein said peptide further comprises a modification to increase the circulating in-vivo half-life of the peptide in a mammal wherein the modification is glycosylation, pegylation or inclusion of non-hydrolyzable bond.
21. A peptide dimer comprising first and second peptides according to claim 1 , 6 , or 8 wherein the peptide dimer binds to VEGFR-3.
22. The peptide dimer according to claim 21 , wherein the first and second peptides comprise the same amino acid sequence.
23. A composition comprising an isolated peptide according to claim 1 , 6 , or 8 in a pharmaceutically acceptable carrier.